ERYTHROMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erythromycin, and what generic alternatives are available?
Erythromycin is a drug marketed by Arbor Pharms Llc, Barr, Encube, Fougera Pharms, Padagis Us, Elkins Sinn, Bausch And Lomb, Pharmaderm, Pharmafair, Sentiss, Paddock Llc, Alpharma Us Pharms, Bausch, Lilly, Pai Holdings Pharm, Pharmobedient Cnsltg, Renaissance Pharma, Epic Pharma Llc, Mylan, Amneal Pharms Co, Torrent, Alembic, Alkem Labs Ltd, Cadila Pharms Ltd, Teva Pharms Usa Inc, Zydus, Zydus Pharms, Lyne, Ivax Sub Teva Pharms, Watson Labs, Cosette, Life Labs, Amneal Pharms, Ani Pharms, Par Pharm Inc, Dista, Naska, Parke Davis, Aurobindo Pharma Usa, Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Nexus, Teva Parenteral, Lederle, and Purepac Pharm. and is included in seventy-six NDAs.
The generic ingredient in ERYTHROMYCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for ERYTHROMYCIN
US Patents: | 0 |
Applicants: | 46 |
NDAs: | 76 |
Finished Product Suppliers / Packagers: | 30 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 134 |
Patent Applications: | 4,278 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ERYTHROMYCIN |
Drug Sales Revenues: | Drug sales revenues for ERYTHROMYCIN |
What excipients (inactive ingredients) are in ERYTHROMYCIN? | ERYTHROMYCIN excipients list |
DailyMed Link: | ERYTHROMYCIN at DailyMed |
Recent Clinical Trials for ERYTHROMYCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assiut University | N/A |
Sohag University | Phase 2/Phase 3 |
Eastern Virginia Medical School | N/A |
Pharmacology for ERYTHROMYCIN
Drug Class | Macrolide Antimicrobial Macrolide |
Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN
Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN
US Patents and Regulatory Information for ERYTHROMYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-002 | Nov 21, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Lederle | ERYTHROMYCIN STEARATE | erythromycin stearate | TABLET;ORAL | 062089-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Amneal Pharms Co | ERYTHROMYCIN | erythromycin | TABLET;ORAL | 209720-001 | Mar 9, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |